	US 11,884,929 B2
	CPMV enhancer elements
Pierre-Olivier Lavoie, Quebec (CA); and Marc-Andre D'Aoust, Quebec (CA)
Assigned to Medicago Inc., Quebec (CA)
Filed by Medicago Inc., Quebec (CA)
Filed on May 21, 2020, as Appl. No. 16/880,583.
Application 16/880,583 is a continuation of application No. 15/110,696, granted, now 11,441,150, previously published as PCT/CA2015/050009, filed on Jan. 8, 2015.
Application 15/110,696 is a continuation in part of application No. PCT/CA2014/050326, filed on Mar. 28, 2014.
Claims priority of provisional application 61/925,852, filed on Jan. 10, 2014.
Prior Publication US 2020/0283784 A1, Sep. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/82 (2006.01); C12N 7/04 (2006.01)

CPC C12N 15/8216 (2013.01) [C12N 7/045 (2013.01); C12N 15/8251 (2013.01)]

19 Claims

1. A nucleic acid molecule comprising:

a first portion consisting of nucleotides 1-160 of SEQ ID NO:1 having a substitution of G115A,

a second portion comprising a plant Kozak sequence, a multiple cloning site, or a combination of a plant Kozak sequence and a multiple cloning site, the second portion positioned 3′ to the first portion, and

a third portion encoding a heterologous protein of interest, the third portion positioned 3′ to the second portion,

wherein the nucleic acid molecule does not comprise nucleotides 161-509of SEQ ID NO:4.